European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
…, TP Hughes, HM Kantarjian, DW Kim… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …
[HTML][HTML] European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
…, TP Hughes, JJWM Janssen, HM Kantarjian, DW Kim… - Leukemia, 2020 - nature.com
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. …
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. …
[HTML][HTML] Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and …
…, SJ Jeon, SL Jung, DW Kim, EK Kim… - Korean journal of …, 2016 - ncbi.nlm.nih.gov
The rate of detection of thyroid nodules and carcinomas has increased with the widespread
use of ultrasonography (US), which is the mainstay for the detection and risk stratification of …
use of ultrasonography (US), which is the mainstay for the detection and risk stratification of …
[HTML][HTML] Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil… - … England Journal of …, 2010 - Mass Medical Soc
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib.
We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients …
We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients …
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
SC Kim, DW Kim, YH Shim, JS Bang, HS Oh… - Journal of controlled …, 2001 - Elsevier
Although the current clinical formulation of paclitaxel (Taxol ® ) has a promising clinical
activity against a wide variety of tumors, it has significant toxic side effects, some of which are …
activity against a wide variety of tumors, it has significant toxic side effects, some of which are …
Evidence for several waves of global transmission in the seventh cholera pandemic
Vibrio cholerae is a globally important pathogen that is endemic in many areas of the world
and causes 3–5 million reported cases of cholera every year. Historically, there have been …
and causes 3–5 million reported cases of cholera every year. Historically, there have been …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
…, J Wang, JJ Kassack Ipiña, DW Kim… - Blood, The Journal …, 2012 - ashpublications.org
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
[HTML][HTML] Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations
…, SL Jung, DW Kim, EK Kim, JY Kim… - Korean journal of …, 2011 - ncbi.nlm.nih.gov
The detection of thyroid nodules has become more common with the widespread use of
ultrasonography (US). US is the mainstay for detecting and making the differential diagnosis of …
ultrasonography (US). US is the mainstay for detecting and making the differential diagnosis of …
[HTML][HTML] PKC-θ knockout mice are protected from fat-induced insulin resistance
JK Kim, JJ Fillmore, MJ Sunshine… - The Journal of …, 2004 - Am Soc Clin Investig
Insulin resistance plays a primary role in the development of type 2 diabetes and may be
related to alterations in fat metabolism. Recent studies have suggested that local accumulation …
related to alterations in fat metabolism. Recent studies have suggested that local accumulation …
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic …
NP Shah, HM Kantarjian, DW Kim, D Réa… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …
Related searches
- dong-wook kim inha university
- dong-wook kim ewha
- dong-wook kim nc park yonsei
- dong-wook kim seoul national university
- dong-wook kim hanyang university
- dong-wook kim krict
- dong-wook kim postech
- dong-wook kim asan
- dong-wook kim hee
- dong-wook kim kang
- dong-wook kim jisoon ihm
- dong-wook kim boston
- dong-wook kim polymer electrolyte
- dong-wook kim seok
- dong-wook kim imatinib
- dong-wook kim yonsei mechanical